MW 475.6 Da, Purity >98%. MG-132, proteasome inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
DKFZp459C139, EC 3.4.25.1, HC7 I, LMPX, MB1, MGC104214, MGC118075, MGC134464, Macropain epsilon chain, Macropain subunit C7-I, Multicatalytic endopeptidase complex epsilon chain, Multicatalytic endopeptidase complex subunit C7 1, Multicatalytic endopeptidase complex subunit C7-I, PSB2_HUMAN, PSB5_HUMAN, PSMB2, PSMB5, PSX large multifunctional protease X, Proteasome (prosome, macropain) subunit beta type 2, Proteasome (prosome, macropain) subunit, beta type, 5, Proteasome beta 2 subunit, Proteasome beta 5 subunit, Proteasome catalytic subunit 3, Proteasome chain 6, Proteasome component C7-I, Proteasome epsilon chain, Proteasome subunit MB1, Proteasome subunit X, Proteasome subunit beta type-2, Proteasome subunit beta type-5, Proteasome subunit, beta-5
MW 475.6 Da, Purity >98%. MG-132, proteasome inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
Soluble in DMSO to 100 mM but unstable for prolonged periods.
Soluble in ethanol to 100 mM.
Proteasome subunit beta type 2 or PSMB2 also known as PSMB5/MB1 is an essential component of the proteasome complex with a molecular weight of approximately 26 kDa. This subunit participates in the assembly of the 20S core protease complex important for protein degradation functions within cells. PSMB2 is ubiquitously expressed in various tissues reflecting its broad role in cellular homeostasis. It contributes to the active sites of the proteasome facilitating the breakdown of ubiquitinated proteins.
The PSMB2 and PSMB5 subunits play a role in regulated protein degradation as part of the ATP-dependent 26S proteasome complex. This complex orchestrates the degradation of unneeded or damaged proteins by proteolysis a chemical reaction that breaks peptide bonds. PSMB2 aids in maintaining protein quality control and cellular regulation by processing peptides into smaller fragments for further degradation or presentation by MHC class I molecules. Its activity is essential for regulating numerous cellular processes including cell cycle control signal transduction and immune responses.
The PSMB2 protein participates in key pathways such as the ubiquitin-proteasome pathway and the NF-κB signaling pathway. Its involvement in these pathways highlights its role in protein homeostasis and immune regulation within cells. The ubiquitin-proteasome pathway relies on several other proteins including ubiquitin itself and E3 ligases which tag proteins for degradation. PSMB2 collaborates with similar subunits to execute regulated protein breakdown ensuring proper cell function and adaptive responses to cellular stress.
PSMB2's dysregulation associates with conditions such as multiple myeloma and certain neurodegenerative disorders like Alzheimer's disease. In multiple myeloma alterations in PSMB2 expression contribute to the enhanced survival of malignant cells which may involve interactions with other proteasome inhibitors like MG132. This connection highlights potential therapeutic avenues targeting proteasome components to ameliorate disease symptoms and progression. In Alzheimer's disease PSMB2 may intertwine with amyloid precursor protein processing influencing pathogenic protein aggregation and neuronal damage.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab141003, MG-132, proteasome inhibitor
Anti-Nrf2 antibody [EP1808Y] ab62352 staining Nrf2 in untreated HeLa cells (top panel) and treated HeLa cells (bottom panel). Cells were treated with 2μM of MG-132 for 18 hours (ab141003). The cells were fixed with 4% paraformaldehyde (10 min) then permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with Anti-Nrf2 antibody [EP1808Y] ab62352 at 1μg/ml concentration and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse monoclonal to alpha Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to rabbit IgG (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 2μg/ml (shown in green) and a goat secondary antibody to mouse IgG (Alexa Fluor® 594) (Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120) at 2μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI.
Image was taken with a confocal microscope (Leica-Microsystems TCS SP8).
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (Human epithelial cell line from cervix adenocarcinoma) cells, treated with 2μM MG-132 (ab141003) for 18 hours or untreated, labeling SQSTM1 / p62 (phospho S349) with Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 at 1/100 dilution, followed by Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889) secondary antibody at 1/200 dilution (green).
Confocal image showing cytoplasmic staining on HeLa cell line. The expression increased after treatment with 2μM MG-132 (ab141003) for 18 hours.
The nuclear counterstain is DAPI (blue).
Tubulin is detected with Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 (Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594)) at 1/200 dilution (red).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat anti-rabbit IgG (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at 1/1000 dilution.
SQSTM1 / p62 (phospho S349) was immunoprecipitated from 0.35 mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate treated with 2μM MG-132 (ab141003) for 18h with Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 at 1/30 dilution.
Western blot was performed from the immunoprecipitate using Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 at 1/1000 dilution.
VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used for detection at 1/10000 dilution.
Lane 1: HeLa treated with 2μM MG-132 (ab141003) for 18h whole cell lysate, 10 μg (Input).
Lane 2: Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 IP in HeLa treated with 2μM MG-132 (ab141003) for 18h whole cell lysate.
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 in HeLa treated with 2μM MG-132 (ab141003) for 18h whole cell lysate.
Blocking and dilution buffer: 5% NFDM/TBST.
All lanes: Immunoprecipitation - Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] (Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324)
Predicted band size: 47 kDa
Exposure time: 10s
Flow cytometric analysis of 4% paraformaldehyde-fixed HeLa (Human epithelial cell line from cervix adenocarcinoma) cells, treated with 2μM MG-132 (ab141003) for 18 hours (red) or untreated (green), labeling SQSTM1 / p62 (phospho S349) with Anti-SQSTM1 / p62 (phospho S349) antibody [EPR20451] ab211324 at 1/500 dilution compared with a rabbit monoclonal IgG isotype control (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730; black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (Alexa Fluor® 488) at 1/2000 dilution was used as the secondary antibody.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com